"RU-486: After two die, Danco Labs warns doctors about dangers."
Danco Labs warns doctors about dangers of 'early option' pill
Stan Guthrie | posted 6/10/2002 12:00AM

2 of 2

Danco refuses to provide sales data, and the FDA does not require this information to be made public. The Wall Street Journal has reported that the New York-based company expects to gain 29 percent of the U.S. abortion market by 2004.
Since abortion was legalized in 1973, American doctors have terminated 39 million pregnancies and about 200 women have died in connection with abortions. In RU-486 clinical trials, abortions were incomplete in 4.7 percent of the cases. Eight percent of the women required a surgical intervention, and 1.2 percent of the women experienced heavy bleeding.
Deeply dissatisfied with FDA handling of RU-486, Rep. Vitter and Sen. Timothy Hutchinson, R-Arkansas, are sponsoring the RU-486 Patient Health and Safety Protection Act. The bill seeks to codify the restrictions the FDA considered but finally abandoned when it approved the drug.
Under this legislation, a doctor who prescribes RU-486 must be qualified to handle complications from an incomplete abortion or ectopic pregnancy and be certified in ultrasound dating of pregnancy and detection of ectopic pregnancy. The doctor must have admitting privileges at a hospital no more than an hour's drive from the doctor's office. After Danco's letter became public, Vitter alerted his colleagues in the House to the new information in hopes of stimulating new support. Lawmakers referred the bill, which has 27 cosponsors, to the House's health subcommittee.
CMDA's Rudd, however, opposes a legislative remedy as interference in the practice of medicine. Rudd believes a better solution is for the FDA to recommend its earlier restrictions. Rudd says such a move would make doctors "very much liable" when something went wrong.
Vitter says he would accept a new regulation rather than a new law, but he does not trust the FDA. "If the FDA would take action that would ensure the same standards as my bill, I would have no problem with it."
Copyright © 2002 Christianity Today. Click for reprint information.
Related Elsewhere
For more newspaper and magazine articles on the abortion debate and RU-486, see Yahoo's full coverage area.
Past Christianity Today articles on RU-486 include:
Doctors Slow to Prescribe Abortion PillSince RU-486's approval, rising safety concerns and common side effects have led to little use. (Oct. 31, 2001)
Counteroffensive Launched on RU-486Abortion-pill critics allege safety concerns overlooked in FDA approval process. (June 15, 2001)
Bush's Prolife Strategy QuestionedWhite House chief of staff says abortion isn't on list of public policy priorities. (June 15, 2001)
Bitter PillsWhat does RU-486 change about abortion? (Dec. 11, 2000)
Activists Respond on RU-486Religious groups from opposite sides are criticizing and hailing the approval of the drug RU-486. (Nov. 13, 2000)
Books & Culture Corner: RU-486 Uncovers a Lie—And It's Not Just About AbortionThink the abortion pill is indicative of postmodernity? You're wrong. (Oct. 2, 2000)
Abortion Pill Seems on Fast TrackFacing apparent "fast-track approval" of RU-486, pro-life activists say they will concentrate on grassroots education. (Sept. 16, 1996)
ReligiousTolerance.org analyzes the abortion pill issue and examines each side's position. Also, the site has an outline of the stages of human development.
The National Right to Life Council looks at a wide range of RU-486 issues, including addressing lingering concerns, looking at unresolved issues and answering common questions.
The RU-486 Files is an anti-RU-486 site with an extensive collection of articles reaching back to 1991.
The Mifeprex (mifepristone) tablets' label is thirteen pages long on the Food and Drug Administration site. It includes a list of possible adverse reactions. Find more information on Mifepristone from Planned Parenthood and the Food and Drug Administration.
Danco Laboratories, a women's health pharmaceutical company, explains how Mifepristone works, retraces the history of its exclusive license to distribute the pill, and discusses seeing a health care provider to obtain the pill.
Andrew Sullivan wrote in The New Republic that "RU-486 is indeed a sort of progress, if a kind fraught with moral danger."